Suresh Chandra Pradhan

Suresh Chandra Pradhan

Auto-generated profile, based on publicly available information

Suresh Chandra Pradhan

Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry 605 006, India

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2009 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
CGC. Girish
C. Girish
BKBidhan Chandra Koner
Bidhan Chandra Koner
SJS. Jayanthi
S. Jayanthi
KRK. Ramachandra Rao
K. Ramachandra Rao
BRB Rajesh
B Rajesh
SPSuresh Chandra Pradhan
Suresh Chandra Pradhan

28 November 2008 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
CGC. Girish
C. Girish
SPSuresh Chandra Pradhan
Suresh Chandra Pradhan

5 December 2011 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
CGChandrashekaran Girish
Chandrashekaran Girish
SPSuresh Chandra Pradhan
Suresh Chandra Pradhan

27 December 2013 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
SKSunitha Kodidela
Sunitha Kodidela
PCPradhan Suresh Chandra
Pradhan Suresh Chandra
BDBiswajit Dubashi
Biswajit Dubashi

28 May 2020 in Genes
Verified
Journal Article
Open access
PDF file
SKSunitha Kodidela
Sunitha Kodidela
PDPatchava Dorababu
Patchava Dorababu
DTDimpal N. Thakkar
Dimpal N. Thakkar
BDBiswajit Dubashi
Biswajit Dubashi
RSRajan Sundaram
Rajan Sundaram
CUChakradhara Rao S Uppugunduri
Chakradhara Rao S Uppugunduri
Genetic variants influencing the pharmacokinetics and/or pharmacodynamics of the chemotherapeutic drugs used in Acute Lymphoblastic Leukemia (ALL) therapy often contribute to the occurrence of treatment related toxicity (TRT). In this study, we explored the association of candidate genetic variants with early hematological TRT (grade 3–4) occurring within the first 100 days of low-dose methotrexate and 6-mercaptopurine based maintenance therapy (n = 73). Fourteen variants in the following candidate genes were genotyped using allele discrimination assay by real-time PCR: ABCB1, DHFR, GGH, FPGS, MTHFR, RFC1, SLCO1B1, TPMT, and NUDT15. Methotrexate polyglutamate (MTXPG3-5) levels in red blood cells were measured by LC-MS/MS. Early hematological TRT (grade 3–4) was seen in 54.9% of patients. The NUDT15c.415T allele was associated with early TRT occurrence [HR: 3.04 (95% CI: 1.5–6.1); p = 0.007]. Sensitivity of early TRT prediction improved (from 30.7% to 89.7%) by considering FPGS variant (rs1544105’T’) carrier status along with NUDT15c.415T allele [HR = 2.7 (1.5–4.7, p = 0.008)]. None of the considered genetic variants were associated with MTXPG3-5 levels, which in turn were not associated with early TRT. NUDT15c.415T allele carrier status could be used as a stratifying marker for Indian ALL patients to distinguish patients at high or low risk of developing early hematological TRT.

1 March 2015 in Journal of Pharmacology and Pharmacotherapeutics
Verified
Journal Article
Open access
PDF file
JFJose Francis
Jose Francis
MPMuthiah Palaniappan
Muthiah Palaniappan
BDBiswajit Dubashi
Biswajit Dubashi
SPSuresh Chandra Pradhan
Suresh Chandra Pradhan
ACAdithan Chandrasekaran
Adithan Chandrasekaran
Objective: To monitor the adverse drug reactions (ADRs) associated with imatinib treatment in patients with chronic myeloid leukemia (CML) in a tertiary care hospital. Materials and Methods: The study was carried out by the Departments of Pharmacology and Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India. The study was carried out from March 2012 to February 2014. The ADRs were reported in a suspected Adverse Drug Reaction Reporting form, provided by the Central Drugs Standard Control Organization (CDSCO), Ministry of Health and Family Welfare, Government of India. The ADRs were analyzed for their pattern, causality and severity. Results: A total of 326 ADRs from 81 patients were reported during the study period. The hematological toxicities were much more prominent than the non-hematological toxicities in this study. The prevalence of thrombocytopenia (21.17%) was higher compared with other reactions. Further analysis showed that most of the ADRs were mild to moderate in nature. The causality assessment revealed that the majority of the ADRs belonged to the possible category. Conclusion: The present study in a tertiary care hospital suggests that hematological toxicities are predominant in CML patients treated with imatinib mesylate. The blood and lymphatic system (38.96%) was the most affected, with imatinib therapy and thrombocytopenia (21.17%) being the most commonly encountered ADRs in the present study. Thorough monitoring of ADRs is warranted for better treatment outcomes.